Prevalence of metabolic dysfunction–associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data
In the US population, MASLD and fibrosis prevalence are high along with obesity and diabetes. Our findings suggest that early detection of chronic liver disease and targeting lifestyle and other modifiable risk factors may slow disease progression toward advanced fibrosis and cirrhosis.
Authors
- Constance E. Ruhl (ORCID: https://orcid.org/0000-0002-8160-9859)
- Aynur Ünalp–Arida (ORCID: https://orcid.org/0009-0002-6370-7241)
Institutions
- National Institutes of Health (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Scientific Consulting Group (US)
Publication Details
- Journal
- Hepatology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1097/hep.0000000000001211
- Citations
- 15
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.80
Funders
- Centers for Disease Control and Prevention
- National Institute of Diabetes and Digestive and Kidney Diseases